Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,741.00-1.90%ETH$2,476.91-3.80%GOLD$4,168.80+0.28%OIL$91.15-0.37%
Smart Investors Daily
SID Premium
OR

NASDAQ · ORMP

Oramed Pharmaceuticals Inc.

Healthcare · Biotechnology

$4.37

Down-$0.17 (-3.89%)

Updated Oct 8, 2026, 11:56 PM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
126.46M
P/E ratio
-5.24
Dividend yield
5.72%
52-week range
$3.15 – $5.47
Volume
84.75K
Avg. volume
162.09K

Price performance · ORMP

ORMP price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

ORMP closed at $4.37 after 21 trading sessions, down 8.58% for the selected period.

Last close
$4.37
Period change
-8.58%
Period low
$4.37
Period high
$4.79
Daily close
View OHLC price history
ORMP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$4.425$4.45$4.35$4.3784.75K
Oct 6, 2026$4.55$4.575$4.36$4.3896.23K
Oct 5, 2026$4.50$4.57$4.43$4.55104.13K
Oct 2, 2026$4.53$4.565$4.39$4.49178.32K
Oct 1, 2026$4.65$4.685$4.4301$4.48272.6K
Sep 30, 2026$4.70$4.72$4.66$4.67129.15K
Sep 29, 2026$4.76$4.795$4.67$4.69170.67K
Sep 28, 2026$4.70$4.78$4.65$4.75110.38K
Sep 25, 2026$4.80$4.90$4.72$4.73177.85K
Sep 24, 2026$4.71$4.8781$4.65$4.79149.32K
Sep 23, 2026$4.74$4.74$4.62$4.72134.8K
Sep 22, 2026$4.71$4.84$4.71$4.75145.23K
Sep 21, 2026$4.76$4.76$4.67$4.7098.05K
Sep 18, 2026$4.65$4.80$4.61$4.74806.11K
Sep 17, 2026$4.70$4.77$4.65$4.67128.04K
Sep 16, 2026$4.63$4.67$4.54$4.62122.77K
Sep 15, 2026$4.64$4.655$4.55$4.62145.85K
Sep 14, 2026$4.64$4.76$4.64$4.67135.1K
Sep 11, 2026$4.81$4.82$4.65$4.66144.53K
Sep 10, 2026$4.74$4.854$4.66$4.76131.47K
Sep 9, 2026$4.94$4.94$4.70$4.78245.69K

Latest ORMP news

The latest Smart Investors Daily articles mentioning ORMP.

Stock researchCompany · Overview

ORMP research

Overview

Company profile and research snapshot.

Company profile

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ORMP recent ratings
DateFirmRatingTarget
Sep 9, 2024HC Wainwright & Co.Neutral—
May 20, 2024HC Wainwright & Co.Neutral—
May 17, 2023Canaccord GenuityHold—
Jan 17, 2023HC Wainwright & Co.Neutral—
Jan 12, 2023Canaccord GenuityHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an updated investor presentation is available on the Company's investor relations website. The presentation provides an overview of Lifeward's strategy to scale its established rehabilitation platform, levera

Yahoo · Jun 25, 2026

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).

Benzinga · Jun 25, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1 earnings came out

Yahoo · Jun 18, 2026

ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community

By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT ORMP shares to be added to the Russell 2000® & Russell 3000® As Oramed Pharmaceuticals (NASDAQ: ORMP) transitions its business model to leverage its strong balance sheet and allocate capital to investments in the biomedical and other areas, the company announced that its shares will be added to the U.S. small-cap Russell 2000® and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By